SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--March 17, 2006--The TOPAZ(R) system for protein crystallization was instrumental in helping GlaxoSmithKline (GSK) solve the structure of cytochrome P450 2D6 -- an enzyme important in the metabolism of a wide variety of drugs. TOPAZ crystallization chips were used to identify positive conditions for crystallization and subsequently to grow P450 2D6 crystals sufficiently large and well ordered for structural analysis. The research was conducted by the GSK Discovery Research Group in Harlow, UK, and the findings are presented in the March 17 issue of the Journal of Biological Chemistry. This structure is one of over 30 generated by customers using the TOPAZ system in the past twelve months.
